Vector Labs Ab05115-10.3 Anti-LASV glycoprotein complex [25.10C], Human IgG1, Fc Silent™, kappa (100 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: 25.10C
Heavy Chain Modification: Fc Silent™
Synonyms: Lassa virus glycoprotein complex; GPC; Pre-glycoprotein polyprotein GP complex; Pre-GP-C; Stable signal peptide; SSP; Glycoprotein G1; GP1; Glycoprotein G2; GP2
Amount: 100 μg
Application Codes Clone: ELISA; Neutralization; in vitro; CryoEM
Shipping Temperature: Wet Ice
Origin Pub PMID: 35730904
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG1
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody is specific for the LASV glycoprotein complex (GPC) from all LASV lineages (I–IV). It binds the GPC-A epitope, a neutralizing site that spans GP1 and GP2 subunits within a single protomer. This antibody does not cross-react with other Old World arenaviruses, such as LCMV or LUJV.
Application Notes: The original antibody (human IgG1) was generated and confirmed to specifically recognize the Lassa virus (LASV) glycoprotein complex (GPC) via ELISA. In vitro, this antibody demonstrated potent neutralizing activity against all four LASV lineages, as shown in pseudovirus assays and Plaque Reduction Neutralization Test (PRNT) (Robinson et al., 2016; PMID: 27161536). A Fab variant of this antibody was generated and tested. Cryo-EM provided insights into the neutralization mechanism—the antibody’s heavy chain primarily contacts residues in GP1 (loop 225–235), essential for binding to the endosomal receptor LAMP1, while the light chain anchors to the GP2 fusion loop. By binding to these epitope sites, the antibody inhibits viral entry by blocking the interaction between LASV GP and LAMP1, preventing membrane fusion and infection. BLI characterization revealed high binding affinity, with apparent KD values of 3.52 nM, 36.1 pM, and <1.00 pM for LASV lineage I (LI) GP, the LI-R95M-GP variant, and LASV lineage IV (LIV) GP, respectively (Buck et al., 2022; PMID: 35730904). This antibody's neutralizing activity was unaffected by any of the seven glycan-knockout mutants (N99, N109, N119, N167, N224, N390, N395) on LASV GPC, as shown in the heat map of IC₅₀ fold-changes. The Fab version of this antibody formed a stable complex with a GPCysRRLL-LPETG-1NOG trimer, as visualized by NS-EM 2D-average images and 3D-maps, confirming that it recognizes the fully cleaved, prefusion GPC trimer with native SKI-1/S1P cleavage and mammalian glycosylation (Li et al., 2022; PMID: 36288283). The original version of this antibody was used as a positive control in a pseudovirus neutralization assay alongside polyclonal antibodies generated in non-human primates and demonstrated near-complete neutralization of wild-type LASV pseudovirus (ppLASV, Josiah strain) at a low concentration (1 μg/ml) (Enriquez et al., 2025; PMID: 40168843).

Product Class:	Purified
Clone ID:	25.10C
Heavy Chain Modification:	Fc Silent™
Synonyms:	Lassa virus glycoprotein complex; GPC; Pre-glycoprotein polyprotein GP complex; Pre-GP-C; Stable signal peptide; SSP; Glycoprotein G1; GP1; Glycoprotein G2; GP2
Amount:	100 μg
Application Codes Clone:	ELISA; Neutralization; in vitro; CryoEM
Shipping Temperature:	Wet Ice
Origin Pub PMID:	35730904
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG1
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody is specific for the LASV glycoprotein complex (GPC) from all LASV lineages (I–IV). It binds the GPC-A epitope, a neutralizing site that spans GP1 and GP2 subunits within a single protomer. This antibody does not cross-react with other Old World arenaviruses, such as LCMV or LUJV.
Application Notes:	The original antibody (human IgG1) was generated and confirmed to specifically recognize the Lassa virus (LASV) glycoprotein complex (GPC) via ELISA. In vitro, this antibody demonstrated potent neutralizing activity against all four LASV lineages, as shown in pseudovirus assays and Plaque Reduction Neutralization Test (PRNT) (Robinson et al., 2016; PMID: 27161536). A Fab variant of this antibody was generated and tested. Cryo-EM provided insights into the neutralization mechanism—the antibody’s heavy chain primarily contacts residues in GP1 (loop 225–235), essential for binding to the endosomal receptor LAMP1, while the light chain anchors to the GP2 fusion loop. By binding to these epitope sites, the antibody inhibits viral entry by blocking the interaction between LASV GP and LAMP1, preventing membrane fusion and infection. BLI characterization revealed high binding affinity, with apparent KD values of 3.52 nM, 36.1 pM, and <1.00 pM for LASV lineage I (LI) GP, the LI-R95M-GP variant, and LASV lineage IV (LIV) GP, respectively (Buck et al., 2022; PMID: 35730904). This antibody's neutralizing activity was unaffected by any of the seven glycan-knockout mutants (N99, N109, N119, N167, N224, N390, N395) on LASV GPC, as shown in the heat map of IC₅₀ fold-changes. The Fab version of this antibody formed a stable complex with a GPCysRRLL-LPETG-1NOG trimer, as visualized by NS-EM 2D-average images and 3D-maps, confirming that it recognizes the fully cleaved, prefusion GPC trimer with native SKI-1/S1P cleavage and mammalian glycosylation (Li et al., 2022; PMID: 36288283). The original version of this antibody was used as a positive control in a pseudovirus neutralization assay alongside polyclonal antibodies generated in non-human primates and demonstrated near-complete neutralization of wild-type LASV pseudovirus (ppLASV, Josiah strain) at a low concentration (1 μg/ml) (Enriquez et al., 2025; PMID: 40168843).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews